Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
about
Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutationsProstate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations.High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.Do Breast Cancer Patients Tested in the Oncology Care Setting Share BRCA Mutation Results with Family Members and Health Care Providers?Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer.Germline Mutations in Predisposition Genes in Pediatric Cancer.An inherited NBN mutation is associated with poor prognosis prostate cancerGermline BRCA mutations denote a clinicopathologic subset of prostate cancer.Markers for detection of prostate cancer.Familial prostate cancer: the damage done and lessons learnt.Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact.Chromosome instability and carcinogenesis: insights from murine models of human pancreatic cancer associated with BRCA2 inactivationNucleic acid-based tissue biomarkers of urologic malignancies.Suggestive evidence of linkage identified at chromosomes 12q24 and 2p16 in African American prostate cancer families from Louisiana.High burden of copy number alterations andc-MYCamplification in prostate cancer fromBRCA2germline mutation carriersFamilial spinal neurofibromatosis due to a multiexonic NF1 gene deletion
P2860
Q28386233-B26061A5-0A5D-47D0-9276-6ADDC157FA99Q34168304-1F549DC0-2DF3-4382-8356-732E62C1EBF8Q34250215-85B19E81-0168-4655-A249-C76753EECD17Q34433513-C86612D9-9CE7-4928-ADE0-41B7E239FB09Q34475135-0C2954A9-10DA-4B1E-B78B-8F28BA4665C4Q34838226-ED7C935B-C7D4-4FFD-BF6F-58425EA3BDBCQ35527158-2663F797-6B29-414E-A4DC-D7B2C412FF1EQ36110947-3E715787-1F79-45B6-98A2-8F74B8739A35Q36118895-B23B829D-14C6-4CF0-B790-A3B13E8B455CQ36524309-D303048A-40FA-4B64-BCC3-7B2B4ED89571Q36594121-96ADB50B-8A2B-4E64-962F-ABC8C1E74878Q37019841-A3CC26F0-DA77-46A3-B9BF-F8EA04CBD8DCQ37328403-3DB2A69D-37FF-482D-8C2F-AFB287536ACCQ37553869-E3A5E460-3B1F-4604-8BCB-10DB3E6085B9Q37581351-82FB57F2-BFFE-42DD-95D7-102C31C03B7AQ37632049-59EA95F9-2E50-4B0E-9EF0-0F211738C6D8Q38165518-DBCAEBED-DCFF-4CBC-9E93-C52C5DDF1A44Q38216131-741C52F7-7AB7-4E9E-ACA8-B035C548C2DCQ46835430-40243447-1DF4-44E7-A022-E19FE9A99398Q57694286-C8963EFA-18B1-47A9-A4F3-419BDF9EB3CAQ58193301-4B2B9FD1-9838-4ACB-A754-7D67C73651C0
P2860
Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Loss of heterozygosity at the ...... ith a germline BRCA2 mutation.
@en
type
label
Loss of heterozygosity at the ...... ith a germline BRCA2 mutation.
@en
prefLabel
Loss of heterozygosity at the ...... ith a germline BRCA2 mutation.
@en
P2093
P50
P1476
Loss of heterozygosity at the ...... with a germline BRCA2 mutation
@en
P2093
Alessandro De Luca
Amber J Willems
John L Hopper
Yoland C Antill
kConFab Investigators
P304
P356
10.1158/1078-0432.CCR-07-5237
P407
P577
2008-04-29T00:00:00Z